References
- Dong W, Zhang Y, Yan M, Liu H, Chen Z, Zhu P. Upregulation of 78-kDa glucose-regulated protein in macrophages in peripheral joints of active ankylosing spondylitis. Scand J Rheumatol 2008;37:427–34.
- McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205–19.
- Yoo SA, You S, Yoon HJ, Kim DH, Kim HS, Lee K, A novel pathogenic role of the ER chaperone GRP78/BiP in rheumatoid arthritis. J Exp Med 2012;209:871–86.
- Yagishita N, Yamasaki S, Nishioka K, Nakajima T. Synoviolin, protein folding and the maintenance of joint homeostasis. Nat Clin Pract Rheumatol 2008;4:91–7.
- Hetz C, Chevet E, Harding HP. Targeting the unfolded protein response in disease. Nat Rev Drug Discov 2013;12:703–19.
- Luo S, Mao C, Lee B, Lee AS. GRP78/BiP is required for cell proliferation and protecting the inner cell mass from apoptosis during early mouse embryonic development. Mol Cell Biol 2006;26:5688–97.
- Cohen M, Omair MA, Keystone EC. Monoclonal antibodies in rheumatoid arthritis. Int J Clin Rheumatol 2013;8:541–56.
- Combe B, van Vollenhoven R. Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples. Ann Rheum Dis 2013;72:1433–5.
- Woodrick RS, Ruderman EM. Safety of biologic therapy in rheumatoid arthritis. Nat Rev Rheumatol 2011;7:639–52.